Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2015—Adaptive Biotechnologies announced a publication in Science Translational Medicine on a novel technology for pairing T-cell receptor alpha and beta chain sequences at high throughput.
November 2015—Mindray received 510(k) clearance to market and sell the Mindray BC-3600 Auto Hematology Analyzer, which aims to meet the testing needs of small and mid-volume hematology laboratories. The BC-3600 Hematology Analyzer features closed-tube sampling via a single push button.
November 2015—Thermo Fisher Scientific received the in vitro diagnostics device CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer, and ClinQuan MD software.
November 2015—Clarient Diagnostics will offer the FDA-approved PD-L1 companion diagnostic, which will help identify patients most likely to benefit from Merck’s lung cancer drug Keytruda.
November 2015—Streck has acquired Fertility Solutions’ sperm count and post-vasectomy quality control products. The sperm count controls for fertility diagnosis have been renamed Sperm-Chex and Sperm-Chex Post VC.
November 2015—Irvine Scientific received CE mark approval for its Human Serum Albumin Solution (100 mg/mL) in normal saline. HSA is used in assisted reproductive procedures as a protein supplement for gamete and embryo manipulation.
Lab Sensor Solutions will partner with MarketLab to distribute T-Tracks, which tracks, in real time, the temperature and location of clinical samples in transit, preventing laboratory specimen spoilage and loss and ensuring regulatory compliance. T-Tracks data are delivered to lab personnel’s desktops, laptops, and mobile devices.
QuanDx announced that its Leukemia Fusion Genes (Q30) Screening Kit has been released as a CE IVD product. The Leukemia Fusion Genes (Q30) product is a qualitative in vitro diagnostic kit for use in a clinical laboratory for the simultaneous detection of 30 fusion genes using a novel multiplex reverse transcription real-time PCR system.
Early results from a randomized trial for lung cancer using autoantibody biomarkers were announced at the International Association for the Study of Lung Cancer’s 16th World Conference on Lung Cancer, held Sept. 6–9 in Denver.
Biocartis launched its CE-IVD Idylla KRAS Mutation Test, a sample-to-result test for the fast, accurate, and reproducible detection of 21 relevant mutations in the KRAS oncogene. The fully automated test, for routine use, detects all clinically relevant driver mutations of the KRAS oncogene in tissue of colorectal cancers at a sensitivity of five percent.
